UPLIFT
is a 4-year COPD landmark trial which compared tiotropium (SPIRIVA
) versus placebo (hereafter referred to "control"), allowing all patients throughout the trial to use all prescribed respiratory medications other than inhaled anticholinergics.
The primary objective of UPLIFT was to determine whether tiotropium reduces the rate of lung function decline (as measured by FEV
) over
4 years in COPD patients. Other important outcome measures – including health-related quality of life, exacerbations of COPD and mortality - will also be assessed.
Please access the online publication
on UPLIFT
from
The New England Journal of Medicine
 |
__ |
M. Decramer et al, COPD J Chronic Obstruct Pulm Dis 1 (2),
303-312 (2004)
If you would like to have access to the entire publication, please refer to
www.informaworld.com
